Research & Development

Five things for pharma marketers to know: Tuesday, April 14

Five things for pharma marketers to know: Tuesday, April 14

By

IBM takes on healthcare data; Mylan settled a lawsuit allowing it to launch generic Viagra by 2017; an FDA committee will meet today to discuss Onglyza

 Five things for pharma marketers to know: Thursday, April 9

Five things for pharma marketers to know: Thursday, April 9

By

Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times

Sanofi R&D lead takes aim at global drug regulations

The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.

Five things for pharma marketers to know: Thursday, March 12

Five things for pharma marketers to know: Thursday, March 12

By

The SEC said some company drug prices can be made public, 23andMe launched an R&D division, and Public Citizen is asking the FDA to withdraw a proposal it says will undermine drug safety information.

Sanofi lays off 100 at Boston R&D hub

The Paris-based drugmaker has axed 100 oncology and global R&D employees as part of a reorganization effort.

Study says pharma may need profit-sustaining help

Study says pharma may need profit-sustaining help

By

Researchers say the golden-age of profits appears to be over, and the industry may need help funding innovation.

Five things for pharma marketers to know: Monday, January 12

Five things for pharma marketers to know: Monday, January 12

By By

BMS halts cancer drug trial over positive Phase-III results; Shire has acquired NPS Pharmaceuticals for $5.2 billion; 23andMe expands Pfizer agreement.

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

By

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Five things for pharma marketers to know: Tuesday, December 16

Five things for pharma marketers to know: Tuesday, December 16

By By

Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.

Tufts: drug dev costs have jumped 145%

Tufts: drug dev costs have jumped 145%

By

Researchers say the average cost of bringing a drug from concept to approval, and through post-approval assessments for reasons such as new doses or formulations, hovers at around $2.8 billion per drug in 2013 dollars.

2015 an "important year" for Pfizer's IO pipeline, analysts say

A 4-1BB agonist highlights a discussion with analysts on the drug giant's immunoncology pipeline, with a number of combination options to be tested next year.

Study shows challenge of CNS drug approvals

For example: Tufts Center for the Study of Drug Development reseachers say it takes 18% longer to develop CNS drugs than it does non-CNS drugs.

Fail-fast doctrine ups late-stage success

Fail-fast doctrine ups late-stage success

By

Thomson Reuters finds the pharmaceutical industry is getting better at abandoning failures earlier.

FDA wants more info on Acura pain drug

FDA wants more info on Acura pain drug

By

FDA feedback will influence a new clinical trial design, but the regulator's recent reaction was a bit of a surprise.

Prosena gets nonprofit boost

CureDuchenne is giving biotech Prosena $7 million to help its Duchenne Muscular Dystrophy treatment move along.

Study finds researchers are social-media shy

Study finds researchers are social-media shy

By

Researchers find worries about being misunderstood or mixed in with "junk" news are among the reasons academic researchers are keeping their data points out of the social media swirl. Researchers say this fear is at the expense of a faster way to make an impact on public policy.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.

Lilly's ramu' has squamous, non-squamous potential

Lilly's ramu' has squamous, non-squamous potential

By

The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.

Big Pharma puts $250M towards disease collaboration

Ten pharma companies will share money and biomarker research under an NIH collaboration.

AstraZeneca closes India R&D shop

168 employees will be pink-slipped this quarter.

Regeneron doubles up on genetics

Regeneron doubles up on genetics

By

The company known for Eylea has launched a genetics discovery unit and teamed up with a partner to sequence 100,000 patient genomes.

Amgen bone-builder bests older meds: trial

Amgen bone-builder bests older meds: trial

By

Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.

Merck moving to regional R&D hubs: WSJ

The move is designed to help the drugmaker pursue more external transactions to bulk up its product line.

Patients sound off on helping pharma find new molecules

Patients sound off on helping pharma find new molecules

By

A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.

BMS narrows its R&D focus

BMS narrows its R&D focus

By

The company's pursuit of a tighter research focus follows a path very much like that of its peers.

Flavor of the week: antibiotics

AstraZeneca and Roche strike antibiotic deals.

Astellas inks neurodegenerative collaboration deal

Monday's announcement builds on a stream of recent R&D relationships.

Shutdown dims lights at FDA, NIH and CDC

Shutdown dims lights at FDA, NIH and CDC

By

The midnight shutdown put 800,000 government employees on leave, including those at the FDA, NIH and CDC.

Business briefs: GlaxoSmithKline and Spectrum

GSK sees a regulatory setback on its once-weekly GLP-1 med, and Spectrum Pharma gets hit with an untitled letter from OPDP on a sales aid for Zevalin.

The complexity of cracking open the data door

The complexity of cracking open the data door

By

Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters